ProCE Banner Activity

Updated AML Classifications and Selecting Therapy for AML Without Actionable Alterations

Slideset Download

Download these slides from a live symposium for the most recent data on updated AML classifications and selecting AML therapy for patients without actionable alterations.

Released: December 09, 2022

Expiration: December 08, 2023

Share

Faculty

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Astellas Text

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Servier Pharmaceuticals

Syndax

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Rigel, Servier, Schrodinger.